Shares of Celldex Therapeutics Inc. (NASDAQ:CLDX) dropped 2.8% on Tuesday . The company traded as low as $4.59 and last traded at $4.59, with a volume of 1,018,871 shares changing hands. The stock had previously closed at $4.72.

CLDX has been the topic of a number of recent analyst reports. Jefferies Group restated a “hold” rating and issued a $4.00 price target on shares of Celldex Therapeutics in a report on Friday, May 6th. Cowen and Company reiterated an “outperform” rating and issued a $12.00 target price on shares of Celldex Therapeutics in a research note on Tuesday, April 19th. Roth Capital reiterated a “buy” rating and issued a $7.00 target price on shares of Celldex Therapeutics in a research note on Tuesday, April 19th. Finally, Wedbush reiterated a “neutral” rating and issued a $3.00 target price on shares of Celldex Therapeutics in a research note on Friday, May 6th. Six research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Celldex Therapeutics currently has an average rating of “Hold” and an average target price of $14.11.

The stock has a 50-day moving average price of $4.48 and a 200-day moving average price of $5.37. The firm’s market capitalization is $460.03 million.

Celldex Therapeutics (NASDAQ:CLDX) last issued its quarterly earnings results on Thursday, May 5th. The biopharmaceutical company reported ($0.35) earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of ($0.35). The business had revenue of $1.30 million for the quarter, compared to analysts’ expectations of $1.06 million. During the same quarter last year, the company earned ($0.33) earnings per share. The firm’s revenue for the quarter was up 160.0% on a year-over-year basis. On average, equities research analysts predict that Celldex Therapeutics Inc. will post ($1.36) earnings per share for the current fiscal year.

Other hedge funds have recently added to or reduced their stakes in the company. Bedell Frazier Investment Counseling LLC raised its stake in Celldex Therapeutics by 9.0% in the fourth quarter. Bedell Frazier Investment Counseling LLC now owns 65,236 shares of the biopharmaceutical company’s stock worth $1,023,000 after buying an additional 5,411 shares during the last quarter. TSP Capital Management Group LLC raised its stake in Celldex Therapeutics by 0.8% in the fourth quarter. TSP Capital Management Group LLC now owns 831,648 shares of the biopharmaceutical company’s stock worth $13,040,000 after buying an additional 6,967 shares during the last quarter. California State Teachers Retirement System raised its stake in Celldex Therapeutics by 1.6% in the fourth quarter. California State Teachers Retirement System now owns 182,509 shares of the biopharmaceutical company’s stock worth $2,862,000 after buying an additional 2,946 shares during the last quarter. ProShare Advisors LLC raised its stake in Celldex Therapeutics by 10.7% in the fourth quarter. ProShare Advisors LLC now owns 93,666 shares of the biopharmaceutical company’s stock worth $1,469,000 after buying an additional 9,072 shares during the last quarter. Finally, Rhumbline Advisers raised its stake in Celldex Therapeutics by 4.9% in the fourth quarter. Rhumbline Advisers now owns 108,426 shares of the biopharmaceutical company’s stock worth $1,700,000 after buying an additional 5,110 shares during the last quarter.

Celldex Therapeutics, Inc is a biopharmaceutical company focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases. The Company is engaged in the development of targeted immunotherapeutics comprised of antibodies, adjuvants and monotherapies and antibody-drug conjugates that treat cancers and other diseases.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.